RECRUITING

EEG Biomarkers for OUD: Diagnostic, Prognostic, and Predictive Applications

Conditions

Opiod Use Disorder opioid use disorder EEG

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The US is suffering from a national opioid epidemic characterized by significant costs, overdoses, and deaths. Conventional Opioid Use Disorder (OUD) treatments (i.e., pharmacological and psychosocial interventions) are characterized by limited or diminishing efficacy, ceiling effects, and/or serious side effects. The availability of validated OUD biomarkers would be a key step in the development and approval of better treatments. Ultimately, the scarcity of OUD biomarkers represents a significant unmet need in the fight against opioid addiction as recognized by NIDA and the FDA with their support for development of Medical Device Development Tools (MDDT) and biomarker tests for OUD. Advances in neuroimaging techniques, and in particular recent evidence supports electroencephalography (EEG) as a promising candidate to investigate the correlation between addiction and brain state. To address the clear medical and market need for OUD biomarkers, this is a feasibility study to identify and assess potential EEG biomarkers for OUD diagnoses, disease monitoring, and prediction of OUD treatment response.

Official Title

Developing EEG Biomarkers for OUD Diagnostic, Prognostic, and Predictive Purposes

Quick Facts

Study Start:2025-02-04

Study Completion:2025-09-15

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT07085351

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:22 Years to 85 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* For OUD Subjects: 1. Providing informed consent to participate in the study. 2. 22 to 85 years old. 4. Lives in immediate area with no plans to relocate. 1. Providing informed consent to participate in the study. 2. 22 to 85 years old. 3. Lives in immediate area with no plans to relocate	* For OUD Subjects: 1. Recently started on antiepileptic drug therapy. 2. Ingestion of poppy seeds or herbal teas containing Papaveris fructus (may cause a positive opiate test for morphine, codeine \[72,73\]). 3. History of neurological disorders involving stroke, brain tumors, or epilepsy as self- reported. 4. History of unexplained fainting spells as self-reported. 5. History of head injury resulting in more than a momentary loss of consciousness as self-reported. 6. History of brain surgery as self-reported. 7. Suffering from severe depression. 8. Active malignancy. 1. Recently started on antiepileptic drug therapy. 2. History of neurological disorders involving stroke, brain tumors, or epilepsy as self- reported. 3. History of unexplained fainting spells as self-reported. 4. History of head injury resulting in more than a momentary loss of consciousness as self-reported. 5. History of brain surgery as self-reported. 6. Suffering from severe depression. 7. Active malignancy.

Inclusion Criteria

Exclusion Criteria

* For OUD Subjects:
1. Providing informed consent to participate in the study.
2. 22 to 85 years old.
4. Lives in immediate area with no plans to relocate.
1. Providing informed consent to participate in the study.
2. 22 to 85 years old.
3. Lives in immediate area with no plans to relocate

* For OUD Subjects:
1. Recently started on antiepileptic drug therapy.
2. Ingestion of poppy seeds or herbal teas containing Papaveris fructus (may cause a positive opiate test for morphine, codeine \[72,73\]).
3. History of neurological disorders involving stroke, brain tumors, or epilepsy as self- reported.
4. History of unexplained fainting spells as self-reported.
5. History of head injury resulting in more than a momentary loss of consciousness as self-reported.
6. History of brain surgery as self-reported.
7. Suffering from severe depression.
8. Active malignancy.
1. Recently started on antiepileptic drug therapy.
2. History of neurological disorders involving stroke, brain tumors, or epilepsy as self- reported.
3. History of unexplained fainting spells as self-reported.
4. History of head injury resulting in more than a momentary loss of consciousness as self-reported.
5. History of brain surgery as self-reported.
6. Suffering from severe depression.
7. Active malignancy.

Contacts and Locations

Study Contact

Aksarapak Hengyotmark, MD

CONTACT

312-257-4158

ahengy2@uic.edu

Study Locations (Sites)

Clinical & Imaging Research Outcomes Lab

Chicago, Illinois, 60612

United States

Collaborators and Investigators

Sponsor: University of Illinois at Chicago

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-04

Study Completion Date2025-09-15

Study Record Updates

Study Start Date2025-02-04

Study Completion Date2025-09-15

Terms related to this study

Keywords Provided by Researchers

opioid use disorder
EEG

Additional Relevant MeSH Terms

Opiod Use Disorder